DAXOR: Funding, Investors & Team (Sep 2026)
DAXOR Corporation is a groundbreaking medical technology company that has created the BVA-100 Blood Volume Analyzer, the first FDA-approved device that can quickly and accurately measure a patient's blood volume. The company believes that this innovative instrument has the potential to revolutionize treatment in various medical and surgical settings. DAXOR aims to collaborate with hospitals and clinics to make this transformation a reality. The BVA-100 is a semi-automated device that requires a single use diagnostic kit, and it is the only FDA-approved instrument for direct blood volume measurement.
DAXOR has raised $15.8M across 5 funding rounds on record, the most recent an undisclosed round of $9.0M announced in Jan 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
DAXOR Company Profile and Key Stats
Latest funding round on record: Jan 2026.
DAXOR Funding Rounds
DAXOR raised $2.1M in an undisclosed round announced in Nov 2022.
6 months later, an undisclosed round of $4.0M was announced in May 2023.
4 months later, an undisclosed round of $350k was announced in Sep 2023.
1 years later, an undisclosed round of $300k was announced in Sep 2024.
1.3 years later, an undisclosed round of $9.0M was announced in Jan 2026.
DAXOR Founders and Leadership Team
No contact details are on record for this team yet.
DAXOR Funding Compared to Other Biotechnology Startups
DAXOR's latest round of $9.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like DAXOR in Biotechnology and New York
Companies Similar to DAXOR
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
DAXOR Funding FAQs
What does DAXOR do?
DAXOR Corporation is a groundbreaking medical technology company that has created the BVA-100 Blood Volume Analyzer, the first FDA-approved device that can quickly and accurately measure a patient's blood volume. The company believes that this innovative instrument has the potential to revolutionize treatment in various medical and surgical settings. DAXOR aims to collaborate with hospitals and clinics to make this transformation a reality. The BVA-100 is a semi-automated device that requires a single use diagnostic kit, and it is the only FDA-approved instrument for direct blood volume measurement.
How much funding has DAXOR raised?
DAXOR has raised $15.8M across 5 rounds on record. The most recent is an undisclosed round of $9.0M announced in Jan 2026.
When did DAXOR last raise funding?
DAXOR's most recent funding round on record is an undisclosed round of $9.0M, announced in Jan 2026.
Who founded DAXOR?
FundedIQ lists Joseph Feldschuh (Founder) at DAXOR.
Where is DAXOR headquartered?
DAXOR is based in New York, United States.
How many employees does DAXOR have?
DAXOR is in the 1-10 employee band.
How does DAXOR's funding compare to other Biotechnology startups?
DAXOR's latest round of $9.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's DAXOR Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for DAXOR is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.